In conclusion, we demonstrate that anti-CTLA-4 antibodies remodel tumor blood vessels and increase TA-HEVs via Fc-dependent mechanisms, and we identify Fc-optimized anti-CTLA-4 antibodies as effective and clinically applicable therapeutic agents for increasing TA-HEVs and T cell antitumor immunity in patients with cancer. The gene discussed is CTLA4; the disease is neoplasm.